Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
复制标题
DOI：
10.1038/s41598-020-65895-0
复制
发表时间：
2020-06-03
影响因子：
4.6
通讯作者：
Sudo, Akihiro
中科院分区：
文献类型：
--
作者：
Asanuma, Kunihiro;Nakamura, Tomoki;Sudo, Akihiro
PD-L1的可溶性形式（sPD-L1）与各种癌症的不良预后有关。尚未报道软组织肿瘤患者肿瘤细胞上表达的sPD-L1和PD-L1的比较。本研究旨在分析软组织肿瘤患者血清sPD-L1和PD-L1水平。共有135例原发性软组织肿瘤患者入组本研究。采用酶免疫分析法定量检测sPD-L1水平，免疫组织化学法检测高级别肉瘤细胞PD-L1表达。良性（48例）和软组织肉瘤（STS）患者（87例）之间的sPD-L1水平无显著差异。在STS中，使用对数秩检验，高sPD-L1（>44.26 pg/mL）组的5年无转移生存期（MS）和总生存期（OS）显著低于低sPDL 1组（=44.26 pg/mL）。在多变量考克斯比例风险分析中，高sPD-L1组与低sPD-L1组相比，MS和OS具有显著差异。阳性和阴性免疫组之间，无复发生存期（RS），MS和OS没有显着差异。免疫组化染色与sPD-L1之间的Kappa系数无相关性。血清sPD-L1水平可预测STS患者的转移和预后。STS患者的高sPD-L1可能是检查点抑制剂治疗的目标。
The soluble form of PD-L1 (sPD-L1) is related to a poor prognosis in various cancers. Comparisons of sPD-L1 and PD-L1 expressed on tumor cells in soft tissue tumor patients have not been reported. The purpose of this study was to analyze serum sPD-L1 and PD-L1 levels in soft tissue tumor patients. A total of 135 patients with primary soft tissue tumors were enrolled in this study. The sPD-L1 level was quantitatively measured by enzyme immunoassay, and PD-L1 expression on high grade sarcoma cells was analyzed immunohistologically. There were no significant differences in sPD-L1 levels between benign (48) and soft tissue sarcoma (STS) patients (87). In STS, the high sPD-L1 (>44.26 pg/mL) group had significantly lower metastasis-free survival (MS) and lower overall survival (OS) than the low sPDL1 group (=44.26 pg/mL) at 5 years using the log-rank test. On multivariate Cox proportional hazard analysis, the high sPD-L1 group had significant differences in MS and OS compared to the low sPD-L1 group. Between positive and negative immunostaining groups, recurrence-free survival (RS), MS, and OS were not significantly different. No correlation was found between immunostaining and sPD-L1 with the Kappa coefficient. The sPD-L1 concentration could predict future metastasis and prognosis in STS patients. High sPD-L1 in STS patients may be a target for treatment with checkpoint inhibitors.